ARCH Venture Management, LLC
CIK 1274403
13F filing for Q2 2026・No. 2,428
- Holdings
- US$1.1B
- Quarter change
- +US$423.17M
- Entries
- 12
- Net bought (estimate)
- +US$314.53M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 3
- Sold out 1
- Cut 1
- Added 0
- Corporate actions 0
- Unchanged 8
Largest holdings
12 stocks worth US$1.1B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| PARABILIS MEDICINES INCCOM | New | 6,412,780 | US$175.52M | 15.95% |
| BEAMBEAM THERAPEUTICS INCCOM | Unchanged | 4,540,132 | US$155.77M | 14.16% |
| RAPPORT THERAPEUTICS INCCOM | Unchanged | 3,728,738 | US$155.38M | 14.12% |
| SEAPORT THERAPEUTICS INCCOMMON STOCK | New | 6,294,951 | US$136.6M | 12.42% |
| ERASCA INCCOM | Unchanged | 7,091,557 | US$129.92M | 11.81% |
| VIR BIOTECHNOLOGY INCCOM | Cut | 12,694,163 | US$129.35M | 11.76% |
| MAZEMAZE THERAPEUTICS INCCOM | Unchanged | 4,120,053 | US$122.98M | 11.18% |
| LYELL IMMUNOPHARMA INCCOM NEW | Unchanged | 3,247,162 | US$45.53M | 4.14% |
| GENBGENERATE BIOMEDICINES INCCOM SHS | Unchanged | 1,944,426 | US$32.8M | 2.98% |
| TXG10X GENOMICS INCCL A COM | Unchanged | 217,834 | US$8.35M | 0.76% |
Sign in (free) to see its 12 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.